Refine
Has Fulltext
- yes (330)
Is part of the Bibliography
- yes (330)
Year of publication
Document Type
- Journal article (330) (remove)
Keywords
- chronic kidney disease (17)
- heart failure (15)
- Fabry disease (13)
- adrenocortical carcinoma (13)
- mortality (12)
- inflammation (11)
- echocardiography (10)
- myocardial infarction (10)
- hemodialysis (9)
- prognosis (8)
- biomarker (7)
- cardiomyopathy (7)
- cortisol (6)
- depression (6)
- heart (6)
- obesity (6)
- therapy (6)
- CXCR4 (5)
- PET (5)
- anxiety (5)
- atherosclerosis (5)
- biomarkers (5)
- blood pressure (5)
- cardiovascular disease (5)
- cardiovascular diseases (5)
- enzyme replacement therapy (5)
- metabolomics (5)
- mouse (5)
- paraganglioma (5)
- pheochromocytoma (5)
- prevalence (5)
- type 2 diabetes (5)
- Cushing’s syndrome (4)
- cardiovascular events (4)
- coronary heart disease (4)
- cytokines (4)
- diabetes mellitus (4)
- diagnosis (4)
- epidemiology (4)
- fibrosis (4)
- hypercortisolism (4)
- hypertension (4)
- ischemic stroke (4)
- miRNA (4)
- mice (4)
- oxidative stress (4)
- radial (4)
- risk factors (4)
- survival (4)
- theranostics (4)
- ACTH (3)
- CMR (3)
- COVID-19 (3)
- FGFR (3)
- Heart failure (3)
- MRI (3)
- SOAT1 (3)
- adrenocortical cancer (3)
- amyloidosis (3)
- blood (3)
- cancer (3)
- cardiac hypertrophy (3)
- cardiac magnetic resonance imaging (3)
- cognitive decline (3)
- cognitive impairment (3)
- coronary artery disease (3)
- desmin (3)
- diabetes (3)
- dialysis (3)
- diet (3)
- end-stage renal disease (3)
- endoradiotherapy (3)
- follow-up (3)
- genetics (3)
- guidelines (3)
- hypertrophic cardiomyopathy (3)
- immune response (3)
- immunohistochemistry (3)
- impact (3)
- kidney (3)
- left ventricular hypertrophy (3)
- liraglutide (3)
- lymphocytes (3)
- machine learning (3)
- management (3)
- medicine (3)
- melanoma (3)
- mitotane (3)
- multicenter (3)
- osteoporosis (3)
- outcomes (3)
- quality of life (3)
- safety (3)
- treatment (3)
- vitamin D (3)
- 18F-FDG (2)
- 4D flow (2)
- C-X-C motif chemokine receptor 4 (2)
- CYP2W1 (2)
- Chronic kidney disease (2)
- Cushing’s disease (2)
- Depression (2)
- Diabetes mellitus (2)
- Enzyme replacement therapy (2)
- FGF-pathway (2)
- Fabry genotype (2)
- Fabry nephropathy (2)
- Fabry phenotype (2)
- GFAP (2)
- Germany (2)
- KDIGO (2)
- Kidney function (2)
- Medicine (2)
- Medizin (2)
- Mortality (2)
- NAFLD (2)
- Neurons (2)
- PPGL (2)
- Positronen-Emissions-Tomografie (2)
- Prevalence (2)
- Quality of life (2)
- Roux-en-Y gastric bypass surgery (2)
- SF-36 (2)
- TAVI (2)
- United States (2)
- WSS (2)
- [68Ga]PentixaFor (2)
- ablation (2)
- acute heart failure (2)
- acute kidney injury (2)
- adenomas (2)
- adrenal (2)
- adrenal cancer (2)
- adrenal crisis (2)
- adrenal insufficiency (2)
- adrenal tumours (2)
- adrenocortical tumors (2)
- age (2)
- aging (2)
- aldosterone (2)
- aneurysm (2)
- antimicrobial resistance (2)
- aortic arch (2)
- arrhythmia (2)
- association (2)
- blood flow (2)
- body mass index (2)
- body weight (2)
- bone (2)
- calcification (2)
- cancer treatment (2)
- carbohydrates (2)
- carcinomas (2)
- cardiac (2)
- cardiac MRI (2)
- cardiac surgery (2)
- cardiology (2)
- cardiovascular genetics (2)
- cardiovascular magnetic resonance (2)
- cardiovascular morbidity (2)
- cardiovascular risk factors (2)
- catecholamines (2)
- chemokine receptor (2)
- chronic cerebrovascular disease (2)
- chronic heart failure (2)
- chronic kidney-disease (2)
- convection volume (2)
- copeptin (2)
- deep learning (2)
- deformation (2)
- dementia (2)
- desmosomes (2)
- dialysis adequacy (2)
- efficacy (2)
- ejection fraction (2)
- gastric bypass (2)
- genome-wide association (2)
- glomerular filtration rate (2)
- glycemic control (2)
- guideline adherence (2)
- hemodiafiltration (2)
- hydrocortisone (2)
- hyperexpression techniques (2)
- identification (2)
- immune cells (2)
- immunotherapy (2)
- insulin resistance (2)
- internal medicine (2)
- kidneys (2)
- left ventricular ejection fraction (2)
- left ventricular mass (2)
- lysosomal storage disease (2)
- magnetic resonance imaging (2)
- mapping (2)
- medullary thyroid carcinoma (2)
- metaanalysis (2)
- mineral metabolism (2)
- morbidity (2)
- mouse models (2)
- multiple myeloma (2)
- myocardial work (2)
- natriuretic peptide (2)
- neuroendocrine tumor (2)
- neurofilament light chain (2)
- pediatric adrenocortical cancer (2)
- pediatric adrenocortical tumor (2)
- pembrolizumab (2)
- peptide tyrosine tyrosine (PYY) (2)
- placebo-controlled trial (2)
- population (2)
- positron emission tomography (2)
- postmenopausal women (2)
- precision medicine (2)
- primary prevention (2)
- prognostic factors (2)
- proteinuria (2)
- pulse wave velocity (2)
- quantification (2)
- radiotherapy (RT) (2)
- randomized controlled trial (2)
- receptor (2)
- recurrence (2)
- regulatory T cells (2)
- renal function (2)
- replacement (2)
- restrictive cardiomyopathy (2)
- sepsis (2)
- sizing (2)
- small interfering RNAs (2)
- stage renal-disease (2)
- stem cell transplantation (2)
- stroke (2)
- sudden cardiac death (2)
- surgery (2)
- therapeutic drug monitoring (2)
- troponin (2)
- tyrosine kinase inhibitor (2)
- uremic toxins (2)
- urine (2)
- validation (2)
- vandetanib (2)
- wall shear stress (2)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-dimensional speckle tracking (1)
- 3 T (1)
- 4D flow MRI (1)
- 7 T (1)
- 7T (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- A-delta fibers (1)
- ACC (1)
- ACC/AHA classification (1)
- ACM (1)
- AKI (1)
- ALT (1)
- ARDS (acute respiratory distress syndrome) (1)
- ARVC (1)
- ASE formula (1)
- ATP generation (1)
- ATRX (1)
- Addison's disease (1)
- Addisons disease (1)
- Adrenocortial carcinomas (1)
- African-americans (1)
- Agalsidase beta (1)
- Akutes Nierenversagen (1)
- Alpha-Galactosidase (1)
- Alpha-galactosidase (1)
- Alzheimer’s dementia (1)
- Amino acids (1)
- Anderson-Fabry Disease (1)
- Angst (1)
- Antigen 4 (1)
- Aorta (1)
- Aortic arch (1)
- Aplastic anemia (1)
- Apoptosis (1)
- Artificial Nuclear Pores (1)
- Atherosclerosis (1)
- Autoimmune-Diseases (1)
- B (1)
- B cells (1)
- BET Inhibitor (1)
- BIRC7 (1)
- BRAF mutation (1)
- BRAF(V600E) mutation (1)
- BRD4 (1)
- Biochemical-Diagnosis (1)
- Bioluminescence (1)
- Brain atrophy (1)
- Brownian ratchet (1)
- CASP (1)
- CCR7 (1)
- CD4+ T-cells (1)
- CD9 (1)
- CIED malfunction; pacemaker (PM) (1)
- CKD (1)
- CML (1)
- COH29 (1)
- COMT (1)
- COPD diagnosis (1)
- COVID‐19 vaccination (1)
- CRH stimulation test (1)
- CTNNB1 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Ca cycling (1)
- Ca2+i handling (1)
- Calcineurin-NFATsignaling (1)
- Calcium Citrate (1)
- Calibration (1)
- Cancer genetics (1)
- Cardiac magnetic resonance imaging (1)
- Cardiac resynchronization therapy defibrillator (1)
- CardioMEMS™ HF-System (1)
- Cardiomyopathy (1)
- Cardiovascular diseases (1)
- Cardiovascular hospitalizations (1)
- Cardiovascular risk factors (1)
- Cardiovascular risk prediction (1)
- Carotid intima-media thickness (CIMT) (1)
- Carotid segment (1)
- Carotid ultrasound (1)
- Catheter Lock Solution (1)
- Catheter-related Bloodstream Infections (CRBSI) (1)
- Cell (1)
- Cell lung canger (1)
- Chronic Kidney-disease (1)
- Chronic heart failure (1)
- Chronic heart-failure (1)
- Chronic kidney-disease (1)
- Clinical prediction rule (1)
- Clinical proteomics (1)
- Clinical trial (1)
- Clinical-trials (1)
- Cognitive decline (1)
- Cohort study (1)
- Comorbidities (1)
- Contrast-enhanced CT (1)
- Copeptin (1)
- Coronavirus Disease 2019 (1)
- Cranial sutures (1)
- Cumulative incidence function (1)
- Cushing (1)
- Cushing syndrome (1)
- Cushing's (1)
- Cushing's disease (1)
- Cushings syndrome (1)
- Cytoskeleton (1)
- D313Y genotype (1)
- DIA-MS (1)
- DNA damage (1)
- DOTATOC (1)
- DSC2 (1)
- DSG2 (1)
- Dendritic Cells (1)
- Depression treatment (1)
- Depressive symptomatology (1)
- Desmoplakin (1)
- Diabetic nephropathies (1)
- Diabetic-nephropathy (1)
- Diagnosis (1)
- Diastocic Dysfunction (1)
- Dipeptidyl-peptidase IV inhibitors (1)
- Discovery (1)
- Disease prevalence (1)
- Diversity (1)
- Dokumentationsqualität (1)
- E/e’ (1)
- ECG (1)
- EMT (1)
- EP Procedures (1)
- ESC (1)
- EUROASPIRE (1)
- EUROASPIRE survey (1)
- Embryos (1)
- Enhancer elements (1)
- Epidemiology (1)
- Eplerenone (1)
- European Society (1)
- Expression (1)
- Extracellular volume (1)
- Extracorporeal membrane oxygenation (1)
- F-18-FDG PET/CT (1)
- FGF21 (1)
- FGFR-inhibitors (1)
- Fabry (1)
- Fabry Disease (FD) (1)
- Fabry cardiomyopathy (1)
- Fabry patient (1)
- Fabry-associated pain (1)
- False positive reactions (1)
- Family Investigation of Nephropathy and Diabetes (1)
- Female patients (1)
- Fibroblast Growth Factor-21 (1)
- Fontan’s Operation (1)
- FoxP3 Expression (1)
- Foxp3 (1)
- Framingham (1)
- G protein coupled receptors (1)
- GH response (1)
- GLA protein UCMGP (1)
- GLP-1 (1)
- GMPcGMP-dependent protein kinase I (1)
- GOLD (1)
- GRAPPA (1)
- Galactosidase-A gene (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- General-population (1)
- Genome-wide association studies (1)
- Glial fibrillary acidic protein (1)
- Globotriaosylceramide (1)
- Glomerular-filtration-rate (1)
- Glycaemic control (1)
- Graves disease (1)
- HEK cells (1)
- HFpEF (1)
- HIV (1)
- HIV diagnosis and management (1)
- HLA (1)
- HUVEC (1)
- Haemodialysis (1)
- Hazards (1)
- Healthcare research (1)
- Heart failure with preserved ejection fraction (1)
- Heart failure with reduced ejection fraction (1)
- Hematopoietic cell transplant (1)
- Hemodialysis-patients (1)
- Hemoglobin A1C (1)
- HiGHmed (1)
- Hindbrain (1)
- Home monitoring (1)
- Homoarginine (1)
- Hypercortisolism (1)
- Hyperkalemia (1)
- Hyperosmotic Stress (1)
- ICD-coding of CKD (1)
- IDH1/2 (1)
- IGF-I (1)
- IMAZA (1)
- IP3 (1)
- Immune-System (1)
- Immunological Self-Tolerance (1)
- Immunosuppression (1)
- Impella (1)
- Infection control (1)
- Insulin therapy (1)
- Intensivtransport (1)
- Interhospitaltransfer (1)
- Interleukin-6 (1)
- Internet of Things devices (1)
- JQ1 (1)
- Juvenile biventricular cardiomyopathy (1)
- KWIC (1)
- Kaposi sarcoma (1)
- Klotho-related molecules (1)
- L-arginine (1)
- LCNEC (1)
- LDL cholesterol (1)
- LMNA (1)
- LND (1)
- LNE (1)
- LV dilatation (1)
- LV mass (1)
- LVNC (1)
- Lag time (1)
- Langzeitbeatmung (1)
- Linagliptin (1)
- Long COVID (1)
- Lyso-Gb3 (1)
- MASS (1)
- MEN1 (1)
- MOLLI (1)
- MR (1)
- MR guidance (1)
- MTL30 (1)
- MUST-Score (1)
- Magnetic resonance imaging (1)
- Mass-spectrometry (1)
- Measurement (1)
- Medullärer Schilddrüsenkrebs (1)
- Memory dysfunction (1)
- Men (1)
- Metanephrine (1)
- Methicillin-resistant staphylococcus aureus (1)
- Methodological quality (1)
- Mfn2 KO mice (1)
- Model (1)
- Molecular Channel Transport (1)
- Molekül (1)
- Morbidity (1)
- Morbus Fabry (1)
- Mouse (1)
- Mouse models (1)
- Multiparameter predictor (1)
- Multiple-Sclerosis (1)
- Myeloma (1)
- Myocardial infarction (1)
- Myocardial-Infarction (1)
- NASH (1)
- NCI-H295R (1)
- NEC (1)
- NET (1)
- NMR (1)
- NOP10 (1)
- NR3C1 (1)
- NSG animals (1)
- Natural-history data (1)
- Neprilysin inhibition (1)
- Network (1)
- New mexico (1)
- NfL (1)
- Non‐ischaemic cardiogenic shock (1)
- Normetanephrine (1)
- Nrf2 (1)
- OAT1 (1)
- OAT3 (1)
- OK cells (1)
- OSI (1)
- OXPHOS (1)
- Observational study (1)
- Onset hypertrophic cardiomyopathy (1)
- Oral antidiabetic drugs (1)
- Outcome survey (1)
- Outcomes (1)
- P-cresyl sulfate (1)
- PD-L1 (1)
- PF-05231023 (1)
- PHQ-9 (1)
- PRO (1)
- PTA (1)
- PWV (1)
- PYY3-36 (1)
- Pain (1)
- Pain-related evoked potentials (1)
- Palmoplantar keratoderma (1)
- Paraganglioma (1)
- Physical impairment (1)
- Plasma (1)
- Positron-emission-tomography (1)
- Postmarketing Experience (1)
- Predictive value of tests (1)
- Predictors (1)
- Preserved Ejection Fraction (1)
- Primary care (1)
- Probabilities (1)
- Prognostic impact (1)
- Progression (1)
- Protein (1)
- Psychopharmakologie (1)
- Psychotherapie (1)
- RAKI (1)
- RNA Expression (1)
- RNAScope (1)
- RNR (1)
- ROS (1)
- RRM2 (1)
- RYGB (1)
- Racial differences (1)
- Raman micro-spectroscopy (1)
- Recognition of depression (1)
- Regression (1)
- Remote device monitoring (1)
- Research design (1)
- Resistance (1)
- Risk (1)
- Risk-factors (1)
- Rotary EXcitation (REX) (1)
- Roux-en-Y Gastric Bypass (1)
- Roux-en-Y gastric bypass (1)
- SARS‐CoV‐2 infection (1)
- SASHA (1)
- SCORE (1)
- SGLT2 inhibitor (1)
- SGLT2 inhibitors (1)
- SNP (1)
- SR Ca leak (1)
- SR/mitochondria metabolic feedback (1)
- SSTR (1)
- ST-elevation myocardial infarction (1)
- STEMI (1)
- SUMO2 (1)
- Sample-sizes (1)
- Sars-CoV-2 (1)
- Self-navigation (1)
- Septal bulge (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Sex-Hormones (1)
- ShMOLLI (1)
- Skull (1)
- Small fiber neuropathy (1)
- Society (1)
- Somites (1)
- Spin echo (1)
- Stage renal-disease (1)
- Stiffness (1)
- Subdistribution (1)
- Sudden cardiac death (1)
- Suppressive Function (1)
- Survival (1)
- Systemic-Lupus-Erythematosus (1)
- Systole (1)
- T cells (1)
- T-cells (1)
- T1 mapping (1)
- T1rho (1)
- T1ρ (1)
- TERT (1)
- TKI (1)
- TNF-alpha (1)
- TT\(_{1rho}\) mapping (1)
- T\(_{1P}\) dispersion (1)
- T\(_{1P}\) mapping (1)
- Tanzania (1)
- Taurolidine (1)
- Teichholz formula (1)
- Test accuracy (1)
- Tests (1)
- Thermodynamics (1)
- Thermodynamik (1)
- Time measurement (1)
- Transport (1)
- Treatment outcome (1)
- Tregs (regulatory T cells) (1)
- USP28 (1)
- USP8 (1)
- Utility (1)
- VAS (1)
- VEMP (1)
- Valvular heart-desease (1)
- Variants (1)
- Ventricular septal rupture (1)
- Weaning (1)
- X-chromosomal inactivation (1)
- XA (1)
- Young-patients (1)
- ZDF rats (1)
- Zebrafish (1)
- Zucker fatty fa/fa rats (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]PentixaTher (1)
- [18F]FDG-PET-CT (1)
- [90Y]PentixaTher (1)
- [99mTc]-Sestamibi scan (1)
- [\(^{68}\)Ga] pentixafor (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- abdominal lymph node metastases (1)
- absorption (1)
- accelerated atherosclerosis (1)
- activated-receptor gamma (1)
- activation (1)
- acute respiratory distress syndrome (1)
- adaptive immune response (1)
- add-on (1)
- adenovirus (1)
- adenoviruses (1)
- adenylyl cyclase signaling cascade (1)
- adjuvant platinum-based chemotherapy (1)
- adjuvant therapy (1)
- adjuvant treatment (1)
- adrenal cortex hormones (1)
- adrenal cortex neoplasms (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenal surgery (1)
- adrenal tumor (1)
- adrenal tumors (1)
- adrenalectomia (1)
- adrenocortical (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical adenoma (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical cell line (1)
- adrenocortical development (1)
- adrenocortical tissues (1)
- adrenocortical tumor (1)
- adult patients (1)
- adverse effects (1)
- afatinib (1)
- agalsidase-beta (1)
- agnoists (1)
- albumin excretion rate (1)
- albuminuria (1)
- alcohol (1)
- alkaline phosphatase (1)
- allocation (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha galactosidase (1)
- alpha-galactosidase-A (1)
- alpha/delta agonist GFT505 (1)
- amphiphilic block copolymer (1)
- anaemia (1)
- anatomy (1)
- anemia (1)
- animal model (1)
- animal models of human disease (1)
- antagonist (1)
- anti-drug antibodies (1)
- anti-myocardial (1)
- antibiotic prescription (1)
- antibodies (1)
- anticoagulation (1)
- antidiabetic agents (1)
- antimicrobial stewardship (1)
- antiphospholipid syndrome (1)
- antiretroviral therapy (1)
- antiretrovirals (1)
- anti‐SARS‐CoV‐2‐spike IgG (1)
- aorta (1)
- aortic valve (1)
- aortic valve disease (1)
- aortic valve disease percutaneous intervention (AVDP) (1)
- aortic valve stenosis (1)
- aortic valve stenosis (AS) (1)
- apolipoprotein E (1)
- apolipoprotein-E (1)
- apoptosis (1)
- arial fibrillation (1)
- arrhythmogenic cardiomyopathy (1)
- arterial elasticity (1)
- arterial stiffening (1)
- astrocytoma (1)
- at-home sampling (1)
- atheriosclerosis (1)
- atherogenic dyslipidaemia (1)
- atherosclerosis risk (1)
- atrial fibrillation (1)
- atypical (1)
- autoantibodies (1)
- autoantibody (1)
- autonomous cortisol secretion (1)
- avascular necrosis (1)
- awareness (1)
- balance (1)
- bardoxolone methyl (1)
- battery depletion (1)
- behavior (1)
- biocompatibility (1)
- bioinformatic clustering (1)
- biomarker prediction (1)
- biopsy (1)
- biopsy findings (1)
- blood coagulation factor XIII (1)
- blood plasma (1)
- blood pressure monitoring (1)
- blood-glucose control (1)
- blood–brain barrier (1)
- bone formation (1)
- bone metabolism (1)
- bone mineral density (1)
- brain natriuretic peptide (1)
- brain pathology (1)
- branched-chain amino acids (1)
- bull’s eye plot (1)
- buparlisib (1)
- c-MYC (1)
- calcineurin signaling cascade (1)
- calcium (1)
- calcium imaging (1)
- canagliflozin (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer risk (1)
- cancer risk factors (1)
- cancer types (1)
- cancer-testis antigens (1)
- candidate genes (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac amyloidosis (1)
- cardiac arrest (1)
- cardiac dysfunction (1)
- cardiac energy metabolism (1)
- cardiac function (1)
- cardiac implantable electronic devices (CIED) (1)
- cardiac implants (1)
- cardiac magnetic resonance (1)
- cardiac pacing (1)
- cardiac resynchronization therapy (CRT) (1)
- cardiac thrombi (1)
- cardiac training group (1)
- cardiac transplantation (1)
- cardiac ventricles (1)
- cardiogenetics (1)
- cardiomyopathies (1)
- cardiopulmonary bypass (1)
- cardiovascular MRI (1)
- cardiovascular care (1)
- cardiovascular death (1)
- cardiovascular drugs (1)
- cardiovascular magnetic-resonance (1)
- cardiovascular mortality (1)
- cardiovascular munster procam (1)
- cardiovascular outcomes (1)
- cardiovascularm disease (1)
- carotid artery disease (1)
- case report (1)
- caspase-3 (1)
- catenin (1)
- catheter tip (1)
- cell biology (1)
- cell cultures (1)
- cell fusion (1)
- cell staining (1)
- cells (1)
- cellular physiology (1)
- central nervous system (1)
- cerebrovascular diseases (1)
- channel transport (1)
- checkpoint inhibitors (1)
- child (1)
- cholesterol (1)
- cholesterol metabolism (1)
- chromosomes (1)
- chronic distress (1)
- chronic heart failure (CHF) (1)
- chronic kidney disease (CKD) (1)
- chronic myeloid leukemia (1)
- chronic thromboembolic pulmonary hypertension (1)
- chronotype (1)
- cigarette smoking (1)
- circadian rhythms (1)
- circadian therapy (1)
- circulating microRNA (1)
- classification (1)
- clearance (1)
- clinical (1)
- clinical data warehouse (1)
- clinical manifestations (1)
- clinical routine data (1)
- clinical study (1)
- clinical systems (1)
- clinical trial (1)
- clonal hematopoiesis of indeterminate potential (1)
- cloning of putative human promoter sequence (1)
- closure AV fistula/AVM (CLAV) (1)
- coa reductase inhibitors (1)
- coagulation (1)
- coaptation line (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- colestilan (1)
- colloids (1)
- color-coded (1)
- combination (1)
- comorbidity (1)
- comparability (1)
- comparative genomic hybridization (1)
- complex (1)
- complex‐valued machine learning (1)
- complication (1)
- comprehensive psychosomatic assessment (1)
- computed tomography (1)
- confounders (1)
- congenital adrenal hyperplasia (1)
- consensus conference (1)
- contact force (1)
- contractility (1)
- converting enzyme-inhibition (1)
- cornea verticillata (1)
- coronary calcification (1)
- coronary-artery calcification (1)
- coronary-heart-disease (1)
- correction (1)
- cortical OAT1 (1)
- cortisol-producing adenoma (1)
- costs (1)
- creatine synthesis (1)
- creatinine (1)
- cryptogenic stroke (1)
- cyclic (1)
- cyclic nucleotides such as cyclic adenosine monophosphate (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytoplasmic staining (1)
- cytosol (1)
- dabrafenib (1)
- data augmentation (1)
- data warehouse (1)
- death rates (1)
- deep-vein thrombosis (1)
- deficient mice (1)
- demography (1)
- desmin-related myopathy (1)
- desminopathy (1)
- desmocollin-2 (1)
- desmoglein-2 (1)
- deubiquitinases (1)
- dexamethasone suppression test (1)
- diabetes complications (1)
- diabetes insipidus (1)
- diabetes mellitus type 2 (1)
- diabetic cardiomyopathy (1)
- diabetic kidney disease (1)
- diabetic mouse (1)
- diabetic nephropathy (1)
- diagnosis in Fabry disease (1)
- diagnostic medicine (1)
- dialysate (1)
- dialyzer membrane (1)
- diastolic dysfunction (1)
- diastolic function (1)
- dietary approaches to stop hypertension (1)
- dietary sodium restriction (1)
- digital Health (1)
- digital phenotyping (1)
- digital subtraction angiography (1)
- dilated cardiomyopathy (1)
- dilated cardiomyopathy with ataxia (1)
- dimensions (1)
- disease (1)
- disease score (1)
- disease severity (1)
- dissection (1)
- distant metastases (1)
- dobutamine stress echocardiography (1)
- documentation quality (1)
- dogs (1)
- double knockout mice (1)
- double-blind (1)
- doule blind (1)
- down regulation (1)
- drug interaction (1)
- drug intoxication (1)
- drug monitoring (1)
- drug therapy (1)
- drug toxicity (1)
- drug transporter (1)
- drug treatment (1)
- drug–drug interactions (DDIs) (1)
- dynamic (1)
- dysfunction (1)
- early prognosis (1)
- early-stage osteonecrosis (1)
- ecological momentary assessment (1)
- ectopic (1)
- eculizumab (1)
- electronic data capture (1)
- electronic health records (1)
- electrophysiology (1)
- electroporation (1)
- empagliflozin (1)
- end stage renal disease (1)
- end-stage kidney disease (1)
- endocrine cancer (1)
- endocrinology (1)
- endogenous hypercortisolism (1)
- endothelial (1)
- endothelial cell interactions (1)
- endothelin-1 (1)
- endovascular (1)
- energy homeostasis (1)
- enoxaparin (1)
- entresto (1)
- entropy production (1)
- environmental health (1)
- environmental impact (1)
- eosinophils (1)
- epithelial markers (1)
- erythropoietin (1)
- euroaspire (1)
- evidence-based practice (1)
- expression (1)
- extended matching questions (1)
- extracellular matrix (1)
- extracellular matrix remodeling (1)
- fabry disease (1)
- factor XI (1)
- factor XII (1)
- failure (1)
- fall (1)
- fatal cardiovascular disease (1)
- fatty acids (1)
- fatty liver (1)
- feature selection (1)
- female Fabry patients (1)
- ferritin (1)
- fetuin A (1)
- fibroblast growth factor-23 (1)
- filamin-C (1)
- flow (1)
- flow dynamics (1)
- flow patterns (1)
- fluorescence resonance energy transfer (1)
- focal semental glomerulosclerosis (1)
- focused surgical approach (1)
- food consumption (1)
- fourth (1)
- fractionation membranev (1)
- fracture (1)
- fragmin (1)
- free energy (1)
- free light chains (1)
- functional magnetic resonance imaging (1)
- functional regurgitation (1)
- gastric cancer (1)
- gefitinib (1)
- gene (1)
- gene expression (1)
- gene variant (1)
- gene-environment interaction (1)
- gene-therapy (1)
- genetic analysis (1)
- genetic loci (1)
- genetic renal disease (1)
- genetically modified animals (1)
- genome-wide association study (1)
- genotype/phenotype correlation (1)
- genotyping (1)
- giant cell arteritis (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glioblastoma (1)
- global outcomes (1)
- glomerular-filtration-rate (1)
- glomerulonephritis (1)
- glucocorticoid excess (1)
- glucocorticoid replacement (1)
- glucocorticoid replacement regimens (1)
- glucocorticoid replacement therapy (1)
- glucose homeostasis (1)
- glucose tolerance test (1)
- graft (1)
- graft versus host disease (1)
- green fluorescent protein (1)
- growth differentiation factor 15 (1)
- growth hormone deficiency (1)
- guideline implementation (1)
- guideline-directed medical therapy (1)
- gut microbiome (1)
- haemodiafiltration (1)
- haemodialysis (1)
- haplotype (1)
- hashimotos-thyroiditis (1)
- healing and remodelling processes (1)
- health care (1)
- health care research (1)
- health economics (1)
- health policy (1)
- health questionnaire (1)
- health risk assessment (1)
- healthcare workers (1)
- hearing loss (1)
- heart disease (1)
- heart failure training group (1)
- heart failure with mid-range ejection fraction (1)
- heart failure with reduced ejection fraction (1)
- heart rate (1)
- heme oxygenase-1 (1)
- hemoglobin (1)
- heodialysis patients (1)
- high denisty lipoprotein (1)
- high dose dexamethasone suppression test (1)
- high-dose atorvastatin (1)
- high-resolution analysis (1)
- hip fracture (1)
- histopathology (1)
- home telemonitoring (1)
- homeostasis (1)
- homeostasisIon channels (1)
- hormones (1)
- hospitalization (1)
- human behaviour (1)
- human serum albumin (1)
- hydroxy-dabrafenib (1)
- hypercholesterolemia (1)
- hyperosmolality (1)
- hyperparathyroidism (1)
- hyperphosphataemia (1)
- hypersensitivity (1)
- hyponatremia (1)
- hypopituitary patients (1)
- hypothalamic gene expression (1)
- iPSC-CMs (1)
- identical twins (1)
- idiopathic osteonecrosis (1)
- imaging (1)
- imaging TTE/TEE (ITTE) (1)
- immune check inhibitor (1)
- immune checkpoint inhibitor (ICI) (1)
- immune-related adverse events (1)
- immunity (1)
- immuno-modulation (1)
- immunoassays (1)
- immunofluorescence (1)
- immunohistochemistry techniques (1)
- immunosenescence (1)
- immunotherapy-induced hypophysitis (1)
- implantable cardioverter defibrillator (ICD) (1)
- implantation (1)
- in silico analysis (1)
- in vivo (1)
- inappropriate prescription (1)
- incidence (1)
- incremental cost-effectiveness ratio (ICER) (1)
- indoxyl sulfate (1)
- induced insulin-release (1)
- inebilizumab (1)
- infarction size (1)
- infection (1)
- infections (1)
- inflammaging (1)
- information extraction (1)
- inherited metabolic disorders (1)
- inos (1)
- insufficiency (1)
- insulin tolerance test (1)
- intake (1)
- intensive care medicine (1)
- intensive care transport (1)
- intensive glucose control (1)
- interhospital transfer (1)
- interleukin-6 (1)
- interleukin-8 (1)
- intermediate filaments (1)
- interparticle interaction (1)
- intragastric balloon (1)
- ionic strength (1)
- ipilimumab (1)
- iron (1)
- ischemia (1)
- ischemia-reperfusion injury (1)
- ischemic (1)
- ischemic acute kidney injury model (1)
- isoproterenol (1)
- isturisa (1)
- italian population (1)
- kidney disease (1)
- kidney disease; (1)
- kidney ischemia/reperfusion injury (1)
- kidney-disease CKD (1)
- kinase (1)
- kinase inhibitors (1)
- kinases (1)
- lactase persistence (1)
- lactic acidosis (1)
- lactose (1)
- large animal models (1)
- late gadolinium enhancement (1)
- laxative (1)
- leaflet (1)
- left lateral wall (1)
- left ventricular geometric abnormality (1)
- left ventricular geometry (1)
- left ventricular mass index (1)
- left ventricular performance (1)
- left ventricular remodeling (1)
- left ventricular thrombusv (1)
- left-ventricular hypertrophy (1)
- leptin system (1)
- lesion formation (1)
- lesion size (1)
- lesions (1)
- leukocyte adhesion (1)
- leukocytes (1)
- lifestyle (1)
- linkage (1)
- lipid droplets (1)
- lipid-lowering therapy (1)
- lipoprotein apheresis (1)
- lipoprotein(a) (1)
- lipoxygenase (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liquid chromatography–tandem mass spectrometry (LC–MS/MS) (1)
- livin (1)
- lncRNA (1)
- long-term ventilation (1)
- longitudinal studies (1)
- loss (1)
- low molecular weight (1)
- low-gradient AS (1)
- lower limit of normal (1)
- lung cancer (1)
- lymph node dissection (1)
- lymph nodes (1)
- lymphadenectomy (1)
- lysosomal storage disorder (1)
- lyso‐Gb3 (1)
- m exercise training (1)
- mHealth (1)
- macrovascular (1)
- magnetic resonance (1)
- magnetic resonance spectroscopy (1)
- magnetic resonsance imaging (1)
- malignant tumors (1)
- malnutrition (1)
- marrow (1)
- mass spectrometry (1)
- mass spectronomy (1)
- meat (1)
- medical data integration center (1)
- medical dialysis (1)
- medical informatics initiative (1)
- medical students (1)
- medical therapy (1)
- medication extraction (1)
- medium cut-off dialyzer (1)
- medullary thyroid cancer (1)
- men born (1)
- menopause (1)
- mental impairment (1)
- mesenchymal markers (1)
- meta-analysis (1)
- metabolically unhealthy obesity (1)
- metabolism (1)
- metachronous (1)
- metastasis (1)
- metastatic (1)
- metformin (1)
- metyrapone (1)
- miR-182-5p (1)
- miR-183 cluster (1)
- miR-483-5p (1)
- mices (1)
- microscopy (1)
- microvascular (1)
- mild (1)
- mineral bone density (1)
- mineralocorticoid antagonist (1)
- minerals (1)
- mitochondria (1)
- mitochondria function and morphology (1)
- mitochondrial mRyR1 (1)
- mitofusin 2 (1)
- mitral valve (1)
- mobile crowdsensing (1)
- mobile health (1)
- model (1)
- modified-release hydrocortisone (1)
- molecular biology (1)
- molecular diagnostics (1)
- molecular medicine (1)
- monocytes (1)
- motion detector (1)
- multi-tyrosine kinase inhibitor (1)
- multidetector computed-tomography (1)
- multiple choice questions (1)
- multiple sclerosis (1)
- multivariate data analysis (1)
- mutation (1)
- mutation databases (1)
- mutation triggers (1)
- mutations (1)
- myocardial aging (1)
- myocardial lipid content (1)
- myocardial work efficiency (1)
- myocardial fibrosis (1)
- myocardial-infarction (1)
- myocardium (1)
- natural history (1)
- natural-history data (1)
- nerve fibers (1)
- neural networks (1)
- neuroblastoma – diagnosis (1)
- neurofibromatosis type 1 (1)
- neuroinflammation (1)
- neurological (1)
- neurological complications (1)
- neurology (1)
- neuromyelitis optica spectrum disorders (1)
- neurons (1)
- neuropathy (1)
- neuroscience (1)
- neutral loss (1)
- neutrophils (1)
- nictric-oxide (1)
- nitric oxide (1)
- nitric oxide synthase (1)
- nivolumab (1)
- non-equilibrium thermodynamics (1)
- non-triggered (1)
- noncontact monitoring (1)
- nontraumatic osteonecrosis of the femoral head (1)
- normal adrenal glands (1)
- normal values (1)
- notch signaling (1)
- nuclear staining (1)
- nutritional counseling (1)
- nutritional medical needs (1)
- nutritional risk screening (1)
- obesity surgery (1)
- observational study (1)
- occupational-status (1)
- oligonucleotides (1)
- on-site examination (1)
- oncology (1)
- oncology outpatients (1)
- openEHR (1)
- operation (1)
- opossum kidney cells (1)
- oral glucose (1)
- organoid (1)
- oscillating biomagnetic fields (1)
- osilodrostat (1)
- osimertinib (1)
- osmotic stimulation (1)
- osteocalcin (1)
- outcome (1)
- overload (1)
- p-cresyl sulfate (1)
- paired (1)
- pandemia (1)
- panel (1)
- papillary (1)
- papillary thyroid carcinoma (PTC) (1)
- parallel imaging (1)
- parathyroid adenoma (1)
- parathyroid carcinoma (1)
- parathyroid hormone (1)
- paravalvular regurgitation (1)
- pathogenesis (1)
- pathophysiology (1)
- patient survival (1)
- patients’ awareness (1)
- pediatric (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical carcinoma (1)
- peptide tyrosine tyrosine 3-36 (PYY3-36) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- percutaneous valve therapy (PVT) (1)
- perioperative chemotherapy (1)
- peritoneal carcinomatosis (1)
- personalised medicine (1)
- personalized antimicrobial therapy (1)
- personalized medicine (1)
- personalized treatment (1)
- pharmacoepidemiology (1)
- pharmacokinetics (1)
- pharmacotherapy (1)
- phase IV (1)
- phase-contrast CMR (1)
- phase-contrast MRI (1)
- pheochromocytoma/paraganglioma (1)
- phosphate homeostasis (1)
- phosphatidylcholines (1)
- phospholipid fatty acids (1)
- phosphorylated tau protein (1)
- phosphorylation (1)
- physical activity (1)
- physicians’ awareness (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- pig (1)
- pioglitazone (1)
- piperacillin/tazobactam (1)
- pituitary (1)
- pituitary adenomas (1)
- pituitary gland (1)
- placebo (1)
- plant-derived metabolites (1)
- plaque (1)
- plaque characteristics (1)
- plasma (1)
- plasma NMR (1)
- plasma proteins (1)
- plasmid construction (1)
- platelet adhesion (1)
- platelets (1)
- pleural mesothelioma (1)
- podocyte (1)
- polarization (1)
- poly(2-oxazoline) (1)
- polyglandular autoimmune syndrome (1)
- polymorphism (1)
- polymyalgia rheumatica (1)
- population pharmacokinetics (1)
- population-based (1)
- population-based study (1)
- posaconazole (1)
- post-traumatic stress disorder (1)
- postoperativ (1)
- posttraumatische Belastungsstörung (1)
- poultry (1)
- preanalytical conditions (1)
- preclinical research (1)
- prediction model (1)
- predictive marker (1)
- premature mortality (1)
- preserved ejection fraction (1)
- preventive medicine (1)
- primary aldosteronism (1)
- primary healthcare (1)
- primary hyperparathyroidism (1)
- primary hypophysitis (1)
- primary polydipsia (1)
- prognostic biomarker (1)
- prognostic marker (1)
- prognostic markers (1)
- progression (1)
- propionic acid (1)
- prospective (1)
- prostaglandin e2 (1)
- prostate cancer (1)
- protein binding (1)
- protein expression (1)
- protein-bound solutes (1)
- protein-bound uremic toxins (1)
- proteomic (1)
- pseudo-severe AS (1)
- psychopharmacology (1)
- psychotherapy (1)
- public health (1)
- pulmonary artery pressure (1)
- pulmonary cancer (1)
- pulse-wave velocity (1)
- quantitative MRI (1)
- radical resection (1)
- radii (1)
- radiofrequency ablation (1)
- radioiodine (1)
- radioiodine therapy (1)
- radiotherapy (1)
- randomized controlled-trial (1)
- randomized trial (1)
- rare diseases (1)
- rat kidney (1)
- ravulizumab (1)
- real-world (1)
- rearranged during transfection (1)
- recombination hotspot (1)
- recommendations (1)
- recovery (1)
- recurrence free survival (1)
- recurrence survival (1)
- recurrence-free survival (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- reference data (1)
- refugee healthcare (1)
- regression analysis (1)
- regulation of expression (1)
- regurgitation (1)
- remote monitoring (1)
- removal (1)
- renal artery (1)
- renal disease (1)
- renal dysfunction (1)
- renal fibrosis (1)
- renal osteodystrophy (1)
- renal replacement therapy (1)
- renal system (1)
- renoprotection (1)
- repeated (1)
- repeated surgery (1)
- reperfusion (1)
- replacement therapy (1)
- reporter gen assay (1)
- reproductive disorders (1)
- research infrastructure (1)
- residual cardiovascular risk (1)
- respiratory signs and symptoms (1)
- retrospective (1)
- review (1)
- re‐transplantation (1)
- rheumatoid arthritis (1)
- right ventricular dysfunction (1)
- risk (1)
- risk factor control (1)
- risk prediction scores (1)
- rodent model (1)
- root (1)
- ruxolitinib (1)
- rygb (1)
- sacubitril-valsartan (1)
- sarcoidosis (1)
- satralizumab (1)
- scale (1)
- sclerostin (1)
- secondary data usage (1)
- secondary prevention (1)
- segmentation (1)
- self-gating (1)
- self-navigation (1)
- selpercatinib (1)
- semantic interoperability (1)
- septal hypertrophy (1)
- sequence databases (1)
- seroprevalence (1)
- serotonin (1)
- serotonin transporter deficient mice (1)
- serum (1)
- serum creatinine (1)
- sevelamer (1)
- severe renal insufficiency (1)
- sex addiction (1)
- sex differences (1)
- shear stress (1)
- shimming (1)
- short Synacthen test (1)
- short term (1)
- short-chain fatty acids (1)
- signal voids (1)
- signs (1)
- signs and symptoms (1)
- single nucleotide polymorphisms (1)
- skin diseases (1)
- sleeve gastrectomy (1)
- small animal (1)
- smoking (1)
- sodium (1)
- sodium-glucose co-transporter-2 inhibitors (1)
- solubility enhancement (1)
- somatic mutations (1)
- somatostatin receptor (1)
- speckle tracking imaging (1)
- speech recognition (1)
- sphingolipids (1)
- spin lock (1)
- spin-lock (1)
- spironolactone (1)
- sports and exercise medicine (1)
- standard heparin (1)
- standardization (1)
- state space (1)
- statement (1)
- statins (1)
- statistical mechanics (1)
- stenosis (1)
- steroid measurement (1)
- stress instructions (1)
- subjective health-status (1)
- sudden death (1)
- sulfonylurea (1)
- super-obesity (1)
- surgical and invasive medical procedures (1)
- surgical oncology (1)
- surgical repair (1)
- surgical treatment (1)
- surveillance (1)
- susceptibility (1)
- symptoms (1)
- systemic micro-inflammation oxidative stress (1)
- systems biology (1)
- t-lymphocytes (1)
- target therapies (1)
- targeted gene panel (1)
- targeted metabolomics (1)
- targeted therapy (1)
- targeted treatment (1)
- task force (1)
- telemedicine (1)
- telomeres (1)
- temperature (1)
- tenting (1)
- term fenofibrate therapy (1)
- therapeutic approach (1)
- therapeutic management (1)
- therapeutic options (1)
- thermodynamics (1)
- third (1)
- three-dimensional echocardiography (1)
- thromboinflammation (1)
- thrombopoiesis (1)
- thyroid carcinoma (TC) (1)
- tight junctions (1)
- timing (1)
- tissue (1)
- tocilizumab (1)
- tomography (1)
- trametinib (1)
- transcatheter valveimplantation (TVI) (1)
- transfection (1)
- transfer learning (1)
- transgenic rats (1)
- translation (1)
- translational research (1)
- transport experiments (1)
- treatment outcome (1)
- trial design (1)
- tricuspid pressure gradient (1)
- triglyceride-rich lipoproteins (1)
- troponin T (1)
- tumor (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tumors (1)
- type 2 (1)
- type-1 diabetes mellitus (1)
- type-2 diabetes mellitus (1)
- tyrosine kinase inhibitor (TKI) (1)
- tyrosine kinase inhibitors (1)
- ublituximab (1)
- ultrahigh field (1)
- ultrahigh-field (1)
- ultrahigh-field MRI (1)
- unfractionated heparin (1)
- univentricular heart (1)
- unsupervised clustering (1)
- uremic toxin (1)
- urinary protein excretion (1)
- usability (1)
- use (1)
- user-centered design (1)
- validity (1)
- variant (1)
- vascular calcification (1)
- vascular surgery (1)
- vemurafenib (1)
- ventricular tachycardia (1)
- vertigo (1)
- viral infection (1)
- vitamins (1)
- volume (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- weaning (1)
- whole exome sequencing (1)
- wires (1)
- yellow fluorescent protein (1)
- zebrafish (1)
- α-galactosidase A (1)
- α‐GalA 3D‐structure (1)
Institute
- Medizinische Klinik und Poliklinik I (330) (remove)
Sonstige beteiligte Institutionen
- Zentraleinheit Klinische Massenspektrometrie (4)
- Apotheke, Universitätsklinikum Würzburg (1)
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Interdisziplinäres Amyloidosezentrum Nordbayern (1)
- Johns Hopkins School of Medicine (1)
- Johns Hopkins University School of Medicine (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Krankenhaushygiene und Antimicrobial Stewardship, Universitätsklinikum Würzburg (1)
Purpose
Pheochromocytomas and Paragangliomas (PPGL) result in chronic catecholamine excess and serious health complications. A recent study obtained a metabolic signature in plasma from PPGL patients; however, its targeted nature may have generated an incomplete picture and a broader approach could provide additional insights. We aimed to characterize the plasma metabolome of PPGL patients before and after surgery, using an untargeted approach, and to broaden the scope of the investigated metabolic impact of these tumors.
Design
A cohort of 36 PPGL patients was investigated. Blood plasma samples were collected before and after surgical tumor removal, in association with clinical and tumor characteristics.
Methods
Plasma samples were analyzed using untargeted nuclear magnetic resonance (NMR) spectroscopy metabolomics. The data were evaluated using a combination of uni- and multi-variate statistical methods.
Results
Before surgery, patients with a nonadrenergic tumor could be distinguished from those with an adrenergic tumor based on their metabolic profiles. Tyrosine levels were significantly higher in patients with high compared to those with low BMI. Comparing subgroups of pre-operative samples with their post-operative counterparts, we found a metabolic signature that included ketone bodies, glucose, organic acids, methanol, dimethyl sulfone and amino acids. Three signals with unclear identities were found to be affected.
Conclusions
Our study suggests that the pathways of glucose and ketone body homeostasis are affected in PPGL patients. BMI-related metabolite levels were also found to be altered, potentially linking muscle atrophy to PPGL. At baseline, patient metabolomes could be discriminated based on their catecholamine phenotype.
Mitochondria are central organelles in the homeostasis of the cardiovascular system via the integration of several physiological processes, such as ATP generation via oxidative phosphorylation, synthesis/exchange of metabolites, calcium sequestration, reactive oxygen species (ROS) production/buffering and control of cellular survival/death. Mitochondrial impairment has been widely recognized as a central pathomechanism of almost all cardiovascular diseases, rendering these organelles important therapeutic targets. Mitochondrial dysfunction has been reported to occur in the setting of drug-induced toxicity in several tissues and organs, including the heart. Members of the drug classes currently used in the therapeutics of cardiovascular pathologies have been reported to both support and undermine mitochondrial function. For the latter case, mitochondrial toxicity is the consequence of drug interference (direct or off-target effects) with mitochondrial respiration/energy conversion, DNA replication, ROS production and detoxification, cell death signaling and mitochondrial dynamics. The present narrative review aims to summarize the beneficial and deleterious mitochondrial effects of common cardiovascular medications as described in various experimental models and identify those for which evidence for both types of effects is available in the literature.
Background. Nitric oxide (NO)-signal transduction plays an important role in renal ischemia/reperfusion (I/R) injury. NO produced by endothelial NO-synthase (eNOS) has protective functions whereas NO from inducible NO-synthase (iNOS) induces impairment. Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist exerted beneficial effects after renal I/R injury, so we investigated whether this might be causally linked with NOS imbalance. Methods. RGZ (5 mg/kg) was administered i.p. to SD-rats (f) subjected to bilateral renal ischemia (60 min). Following 24 h of reperfusion, inulin-and PAH-clearance as well as PAH-net secretion were determined. Morphological alterations were graded by histopathological scoring. Plasma NOx-production was measured. eNOS and iNOS expression was analyzed by qPCR. Cleaved caspase 3 (CC3) was determined as an apoptosis indicator and ED1 as a marker of macrophage infiltration in renal tissue. Results. RGZ improves renal function after renal I/R injury (PAH-/inulin-clearance, PAH-net secretion) and reduces histomorphological injury. Additionally, RGZ reduces NOx plasma levels, ED-1 positive cell infiltration and CC3 expression. iNOS-mRNA is reduced whereas eNOS-mRNA is increased by RGZ. Conclusion. RGZ has protective properties after severe renal I/R injury. Alterations of the NO pathway regarding eNOS and iNOS could be an explanation of the underlying mechanism of RGZ protection in renal I/R injury.
The objective of this study was to identify unknown modulators of Calcineurin (Cn)-NFAT signaling. Measurement of NFAT reporter driven luciferase activity was therefore utilized to screen a human cardiac cDNA-library (~10\(^{7}\) primary clones) in C2C12 cells through serial dilutions until single clones could be identified. This extensive screening strategy culminated in the identification of SUMO2 as a most efficient Cn-NFAT activator. SUMO2-mediated activation of Cn-NFAT signaling in cardiomyocytes translated into a hypertrophic phenotype. Prohypertrophic effects were also observed in mice expressing SUMO2 in the heart using AAV9 (Adeno-associated virus), complementing the in vitro findings. In addition, increased SUMO2-mediated sumoylation in human cardiomyopathy patients and in mouse models of cardiomyopathy were observed. To decipher the underlying mechanism, we generated a sumoylation-deficient SUMO2 mutant (ΔGG). Surprisingly, ΔGG replicated Cn-NFAT-activation and the prohypertrophic effects of native SUMO2, both in vitro and in vivo, suggesting a sumoylation-independent mechanism. Finally, we discerned a direct interaction between SUMO2 and CnA, which promotes CnA nuclear localization. In conclusion, we identified SUMO2 as a novel activator of Cn-NFAT signaling in cardiomyocytes. In broader terms, these findings reveal an unexpected role for SUMO2 in cardiac hypertrophy and cardiomyopathy, which may open the possibility for therapeutic manipulation of this pathway.
Physical and mental well-being during the COVID-19 pandemic is typically assessed via surveys, which might make it difficult to conduct longitudinal studies and might lead to data suffering from recall bias. Ecological momentary assessment (EMA) driven smartphone apps can help alleviate such issues, allowing for in situ recordings. Implementing such an app is not trivial, necessitates strict regulatory and legal requirements, and requires short development cycles to appropriately react to abrupt changes in the pandemic. Based on an existing app framework, we developed Corona Health, an app that serves as a platform for deploying questionnaire-based studies in combination with recordings of mobile sensors. In this paper, we present the technical details of Corona Health and provide first insights into the collected data. Through collaborative efforts from experts from public health, medicine, psychology, and computer science, we released Corona Health publicly on Google Play and the Apple App Store (in July 2020) in eight languages and attracted 7290 installations so far. Currently, five studies related to physical and mental well-being are deployed and 17,241 questionnaires have been filled out. Corona Health proves to be a viable tool for conducting research related to the COVID-19 pandemic and can serve as a blueprint for future EMA-based studies. The data we collected will substantially improve our knowledge on mental and physical health states, traits and trajectories as well as its risk and protective factors over the course of the COVID-19 pandemic and its diverse prevention measures.
Background and Aims
Chronic kidney disease (CKD) is a risk factor for development and progression of heart failure (HF). CKD and HF share common risk factors, but few data exist on the prevalence, signs and symptoms as well as correlates of HF in populations with CKD of moderate severity. We therefore aimed to examine the prevalence and correlates of HF in the German Chronic Kidney Disease (GCKD) study, a large observational prospective study.
Methods and Results
We analyzed data from 5,015 GCKD patients aged 18-74 years with an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73m\(^{2}\) or with an eGFR >= 60 and overt proteinuria (>500 mg/d). We evaluated a definition of HF based on the Gothenburg score, a clinical HF score used in epidemiological studies (Gothenburg HF), and self-reported HF. Factors associated with HF were identified using multivariable adjusted logistic regression. The prevalence of Gothenburg HF was 43% (ranging from 24% in those with eGFR >90 to 59% in those with eGFR<30 ml/min/1.73m2). The corresponding estimate for self-reported HF was 18% (range 5%-24%). Lower eGFR was significantly and independently associated with the Gothenburg definition of HF (p-trend <0.001). Additional significantly associated correlates included older age, female gender, higher BMI, hypertension, diabetes mellitus, valvular heart disease, anemia, sleep apnea, and lower educational status.
Conclusions
The burden of self-reported and Gothenburg HF among patients with CKD is high. The proportion of patients who meet the criteria for Gothenburg HF in a European cohort of patients with moderate CKD is more than twice as high as the prevalence of self-reported HF. However, because of the shared signs, symptoms and medications of HF and CKD, the Gothenburg score cannot be used to reliably define HF in CKD patients. Our results emphasize the need for early screening for HF in patients with CKD.
Background
Solitary metastases to the pancreas are rare. Therefore the value of resection in curative intention remains unclear. In the literature there are several promising reports about resection of solitary metastasis to the pancreas mainly of renal origin.
Case presentation
Here we report for the first time on the surgical therapy of a 1.5 cm solitary pancreatic metastasis of an adrenocortical carcinoma. The metastasis occurred almost 6 years after resection of the primary tumor. A partial pancreatoduodenectomy was performed and postoperatively adjuvant mitotane treatment was initiated. During the follow-up of 3 years after surgery no evidence of tumor recurrence occurred.
Conclusion
Resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.
Impact of Interparticle Interaction on Thermodynamics of Nano-Channel Transport of Two Species
(2020)
Understanding the function and control of channel transport is of paramount importance for cell physiology and nanotechnology. In particular, if several species are involved, the mechanisms of selectivity, competition, cooperation, pumping, and its modulation need to be understood. What lacks is a rigorous mathematical approach within the framework of stochastic thermodynamics, which explains the impact of interparticle in-channel interactions on the transport properties of the respective species. To achieve this, stochastic channel transport of two species is considered in a model, which different from mean field approaches, explicitly conserves the spatial correlation of the species within the channel by analysis of the stochastic dynamics within a state space, the elements of which are the channel’s spatial occupation states. The interparticle interactions determine the stochastic transitions between these states. Local flow and entropy production in this state space reveal the respective particle flows through the channel and the intensity of the Brownian ratchet like rectifying forces, which these species exert mutually on each other, together with its thermodynamic effectiveness and costs. Perfect coupling of transport of the two species is realized by an attractive empty channel and strong repulsive forces between particles of the same species. This confines the state space to a subspace with circular topology, in which the concentration gradients as thermodynamic driving forces act in series, and channel flow of both species becomes equivalent. For opposing concentration gradients, this makes the species with the stronger gradient the driving, positive entropy producing one; the other is driven and produces negative entropy. Gradients equal in magnitude make all flows vanish, and thermodynamic equilibrium occurs. A differential interparticle interaction with less repulsive forces within particles of one species but maintenance of this interaction for the other species adds a bypass path to this circular subspace. On this path, which is not involved in coupling of the two species, a leak flow of the species with less repulsive interparticle interaction emerges, which is directed parallel to its concentration gradient and, hence, produces positive entropy here. Different from the situation with perfect coupling, appropriate strong opposing concentration gradients may simultaneously parallelize the flow of their respective species, which makes each species produce positive entropy. The rectifying potential of the species with the bypass option is diminished. This implies the existence of a gradient of the other species, above which its flow and gradient are parallel for any gradient of the less coupled species. The opposite holds for the less coupled species. Its flow may always be rectified and turned anti-parallel to its gradient by a sufficiently strong opposing gradient of the other one.
Thermodynamics of Competitive Molecular Channel Transport: Application to Artificial Nuclear Pores
(2010)
In an analytical model channel transport is analyzed as a function of key parameters, determining efficiency and selectivity of particle transport in a competitive molecular environment. These key parameters are the concentration of particles, solvent-channel exchange dynamics, as well as particle-in-channel- and interparticle interaction. These parameters are explicitly related to translocation dynamics and channel occupation probability. Slowing down the exchange dynamics at the channel ends, or elevating the particle concentration reduces the in-channel binding strength necessary to maintain maximum transport. Optimized in-channel interaction may even shift from binding to repulsion. A simple equation gives the interrelation of access dynamics and concentration at this transition point. The model is readily transferred to competitive transport of different species, each of them having their individual in-channel affinity. Combinations of channel affinities are determined which differentially favor selectivity of certain species on the cost of others. Selectivity for a species increases if its in-channel binding enhances the species’ translocation probablity when compared to that of the other species. Selectivity increases particularly for a wide binding site, long channels, and fast access dynamics. Recent experiments on competitive transport of in-channel binding and inert molecules through artificial nuclear pores serve as a paradigm for our model. It explains qualitatively and quantitatively how binding molecules are favored for transport at the cost of the transport of inert molecules.
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patients with ACC. We conducted a multicenter retrospective analysis on 154 ACC patients treated for ≥12 months with adjuvant mitotane after radical surgery and who were free of disease at the mitotane stop. During a median follow-up of 38 months, 19 patients (12.3%) experienced recurrence. We calculated the RFS after mitotane (RFSAM), from the landmark time-point of mitotane discontinuation, to overcome immortal time bias. We found a wide variability in the duration of adjuvant mitotane treatment among different centers and also among patients cared for at the same center, reflecting heterogeneous practice. We did not find any survival advantage in patients treated for longer than 24 months. Moreover, the relationship between treatment duration and the frequency of ACC recurrence was not linear after stratifying our patients in tertiles of length of adjuvant treatment. In conclusion, the present findings do not support the concept that extending adjuvant mitotane treatment over two years is beneficial for ACC patients with low to moderate risk of recurrence.
Chronotype is defined as the behavioral manifestation of circadian rhythms related to the external light–dark cycle. Evening chronotype has been associated with an increased risk of developing cardiometabolic diseases in obesity. Menopause is a lifestage associated with an increased risk of developing cardiometabolic diseases and a change in circadian rhythmicity compared to pre-menopause. However, the prevalence of chronotype categories in menopause and their role in determining menopause-related cardiometabolic risk, mostly in obesity, have not been investigated. Thus, we aimed to investigate the prevalence of chronotype categories in post-menopausal women with obesity and their role in menopause-related cardiometabolic risk. In this cross-sectional study we enrolled 49 pre-menopausal and 74 post-menopausal women with obesity. Anthropometric parameters, lifestyle habits, adherence to the Mediterranean Diet (MD), sleep quality, chronotype and the presence of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) were studied. No significance differences were detected in terms of lifestyle and adherence to the MD between pre- and post-menopausal women. Chronotype was classified as morning in 66 (53.6%), evening in 20 (16.3%) and intermediate in 37 (30.1%) women. In addition, pre-menopausal women with obesity showed a significantly higher chance to have an intermediate chronotype (OR = 2.21, 95% CI 1.28–3.83; p = 0.004), whereas post-menopausal women with obesity showed a trend to have a higher morning chronotype (OR = 1.42, 95% CI 0.98–2.06; p = 0.051), although this did not reach statistical significance. No significant differences were detected in terms of prevalence of evening chronotype between the two groups. However, the evening chronotype had a significantly higher risk to have T2DM compared to the morning (OR = 17.29, 95% CI 2.40–124.27; p = 0.005) and intermediate chronotypes (OR = 30.86, 95% CI 2.05–464.32; p = 0.013) in both pre- and post-menopausal women with obesity. In conclusion, the intermediate chronotype was significantly more prevalent in pre-menopausal women with obesity compared to post-menopausal women. Evening chronotype was associated to T2DM in both pre- and post-menopause. These results support the importance of including the assessment of chronotype in the management of women with obesity in post-menopause.
Although bariatric surgery is known to change the metabolome, it is unclear if this is specific for the intervention or a consequence of the induced bodyweight loss. As the weight loss after Roux-en-Y Gastric Bypass (RYGB) can hardly be mimicked with an evenly effective diet in humans, translational research efforts might be helpful. A group of 188 plasma metabolites of 46 patients from the randomized controlled Würzburg Adipositas Study (WAS) and from RYGB-treated rats (n = 6) as well as body-weight-matched controls (n = 7) were measured using liquid chromatography tandem mass spectrometry. WAS participants were randomized into intensive lifestyle modification (LS, n = 24) or RYGB (OP, n = 22). In patients in the WAS cohort, only bariatric surgery achieved a sustained weight loss (BMI −34.3% (OP) vs. −1.2% (LS), p ≤ 0.01). An explicit shift in the metabolomic profile was found in 57 metabolites in the human cohort and in 62 metabolites in the rodent model. Significantly higher levels of sphingolipids and lecithins were detected in both surgical groups but not in the conservatively treated human and animal groups. RYGB leads to a characteristic metabolomic profile, which differs distinctly from that following non-surgical intervention. Analysis of the human and rat data revealed that RYGB induces specific changes in the metabolome independent of weight loss.
Background
Kaposi sarcoma (KS) is a malignant disease most commonly diagnosed in the setting of a human immunodeficiency virus (HIV) infection and in patients receiving immunosuppressive treatment. Pulmonary KS has never been reported in association with endogenous Cushing’s syndrome (CS).
Case presentation
A 60-year-old woman presented with symptoms and signs of CS. Adrenal CS was confirmed by standard biochemical evaluation. Imaging revealed a right adrenal lesion (diameter 3.5 cm) and multiple pulmonary nodules, suggesting a cortisol-secreting adrenal carcinoma with pulmonary metastases. The patient underwent right adrenalectomy with a pathohistological diagnosis of an adrenal adenoma. Subsequent thoracoscopic wedge resection of one lung lesion revealed pulmonary KS with positive immunostaining for human herpes virus 8 (HHV-8). HIV-serology was negative. Hydrocortisone replacement was initiated for secondary adrenal insufficiency after surgery. Post-operative follow up imaging showed complete remission of all KS-related pulmonary nodules solely after resolution of hypercortisolism.
Conclusion
KS may occur in the setting of endogenous CS and may go into remission after cure of hypercortisolism without further specific treatment.
Background: Endovascular therapy is the gold standard in patients with hemodynamic relevant renal artery stenosis (RAS) resistant to medical therapy. The severity grading of the stenosis as well as the result assessment after endovascular approach is predominantly based on visible estimations of the anatomic appearance. We aim to investigate the application of color-coded DSA parameters to gain hemodynamic information during endovascular renal artery interventions and for the assessment of the procedures technical success.
Methods: We retrospectively evaluated 32 patients who underwent endovascular renal artery revascularization and applied color-coded summation imaging on selected monochromatic DSA images. The differences in time to peak (dTTP) of contrast enhancement in predefined anatomical measuring points were analyzed. Furthermore, differences in systolic blood pressure values (SBP) and serum creatinine were obtained. The value of underlying diabetes mellitus as a predictor for clinical outcome was assessed. Correlation analysis between the patients gender as well as the presence of diabetes mellitus and dTTP was performed.
Results: Endovascular revascularization resulted in statistically significant improvement in 4/7 regions of interest. Highly significant improvement of perfusion in terms of shortened TTP values could be found at the segmental artery level and in the intrastenotical segment (p<0.001), significant improvement prestenotical and in the apical renal parenchyma (p<0.05). In the other anatomic regions, differences revealed not to be significant. Differences between SBP and serum creatinine levels before and after the procedure were significant (p=0.004 and 0.0004). Patients ' gender as well as the presence of diabetes mellitus did not reveal to be predictors for the clinical success of the procedure. Furthermore, diabetes and gender did not show relevant correlation with dTTP in the parenchymal measuring points.
Conclusions: The supplementary use of color-coding DSA and the data gained from parametric images may provide helpful information in the evaluation of the procedures ' technical success. The segmental artery might be a particularly suitable vascular territory for analyzing differences in blood flow characteristics. Further studies with larger cohorts are needed to further confirm the diagnostic value of this technique.
In Eurotransplant kidney allocation system (ETKAS), candidates can be considered unlimitedly for repeated re‐transplantation. Data on outcome and benefit are indeterminate. We performed a retrospective 15‐year patient and graft outcome data analysis from 1464 recipients of a third or fourth or higher sequential deceased donor renal transplantation (DDRT) from 42 transplant centers. Repeated re‐DDRT recipients were younger (mean 43.0 vs. 50.2 years) compared to first DDRT recipients. They received grafts with more favorable HLA matches (89.0% vs. 84.5%) but thereby no statistically significant improvement of patient and graft outcome was found as comparatively demonstrated in 1st DDRT. In the multivariate modeling accounting for confounding factors, mortality and graft loss after 3rd and ≥4th DDRT (P < 0.001 each) and death with functioning graft (DwFG) after 3rd DDRT (P = 0.001) were higher as compared to 1st DDRT. The incidence of primary nonfunction (PNF) was also significantly higher in re‐DDRT (12.7%) than in 1st DDRT (7.1%; P < 0.001). Facing organ shortage, increasing waiting time, and considerable mortality on dialysis, we question the current policy of repeated re‐DDRT. The data from this survey propose better HLA matching in first DDRT and second DDRT and careful selection of candidates, especially for ≥4th DDRT.
Background:
Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo.
Methods:
In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection.
Results:
We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection.
Conclusions:
Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.
Context:
Adrenal tumors have a prevalence of around 2% in the general population. Adrenocortical carcinoma (ACC) is rare but accounts for 2–11% of incidentally discovered adrenal masses. Differentiating ACC from adrenocortical adenoma (ACA) represents a diagnostic challenge in patients with adrenal incidentalomas, with tumor size, imaging, and even histology all providing unsatisfactory predictive values.
Objective:
Here we developed a novel steroid metabolomic approach, mass spectrometry-based steroid profiling followed by machine learning analysis, and examined its diagnostic value for the detection of adrenal malignancy.
Design:
Quantification of 32 distinct adrenal derived steroids was carried out by gas chromatography/mass spectrometry in 24-h urine samples from 102 ACA patients (age range 19–84 yr) and 45 ACC patients (20–80 yr). Underlying diagnosis was ascertained by histology and metastasis in ACC and by clinical follow-up [median duration 52 (range 26–201) months] without evidence of metastasis in ACA. Steroid excretion data were subjected to generalized matrix learning vector quantization (GMLVQ) to identify the most discriminative steroids.
Results:
Steroid profiling revealed a pattern of predominantly immature, early-stage steroidogenesis in ACC. GMLVQ analysis identified a subset of nine steroids that performed best in differentiating ACA from ACC. Receiver-operating characteristics analysis of GMLVQ results demonstrated sensitivity = specificity = 90% (area under the curve = 0.97) employing all 32 steroids and sensitivity = specificity = 88% (area under the curve = 0.96) when using only the nine most differentiating markers.
Conclusions:
Urine steroid metabolomics is a novel, highly sensitive, and specific biomarker tool for discriminating benign from malignant adrenal tumors, with obvious promise for the diagnostic work-up of patients with adrenal incidentalomas.
Purpose
Artificial neural networks show promising performance in automatic segmentation of cardiac MRI. However, training requires large amounts of annotated data and generalization to different vendors, field strengths, sequence parameters, and pathologies is limited. Transfer learning addresses this challenge, but specific recommendations regarding type and amount of data required is lacking. In this study, we assess data requirements for transfer learning to experimental cardiac MRI at 7T where the segmentation task can be challenging. In addition, we provide guidelines, tools, and annotated data to enable transfer learning approaches by other researchers and clinicians.
Methods
A publicly available segmentation model was used to annotate a publicly available data set. This labeled data set was subsequently used to train a neural network for segmentation of left ventricle and myocardium in cardiac cine MRI. The network is used as starting point for transfer learning to 7T cine data of healthy volunteers (n = 22; 7873 images) by updating the pre-trained weights. Structured and random data subsets of different sizes were used to systematically assess data requirements for successful transfer learning.
Results
Inconsistencies in the publically available data set were corrected, labels created, and a neural network trained. On 7T cardiac cine images the model pre-trained on public imaging data, acquired at 1.5T and 3T, achieved DICE\(_{LV}\) = 0.835 and DICE\(_{MY}\) = 0.670. Transfer learning using 7T cine data and ImageNet weight initialization improved model performance to DICE\(_{LV}\) = 0.900 and DICE\(_{MY}\) = 0.791. Using only end-systolic and end-diastolic images reduced training data by 90%, with no negative impact on segmentation performance (DICE\(_{LV}\) = 0.908, DICE\(_{MY}\) = 0.805).
Conclusions
This work demonstrates and quantifies the benefits of transfer learning for cardiac cine image segmentation. We provide practical guidelines for researchers planning transfer learning projects in cardiac MRI and make data, models, and code publicly available.
Growth, ageing and atherosclerotic plaque development alter the biomechanical forces acting on the vessel wall. However, monitoring the detailed local changes in wall shear stress (WSS) at distinct sites of the murine aortic arch over time has been challenging. Here, we studied the temporal and spatial changes in flow, WSS, oscillatory shear index (OSI) and elastic properties of healthy wildtype (WT, n = 5) and atherosclerotic apolipoprotein E-deficient (Apoe\(^{−/−}\), n = 6) mice during ageing and atherosclerosis using high-resolution 4D flow magnetic resonance imaging (MRI). Spatially resolved 2D projection maps of WSS and OSI of the complete aortic arch were generated, allowing the pixel-wise statistical analysis of inter- and intragroup hemodynamic changes over time and local correlations between WSS, pulse wave velocity (PWV), plaque and vessel wall characteristics. The study revealed converse differences of local hemodynamic profiles in healthy WT and atherosclerotic Apoe\(^{−/−}\) mice, and we identified the circumferential WSS as potential marker of plaque size and composition in advanced atherosclerosis and the radial strain as a potential marker for vascular elasticity. Two-dimensional (2D) projection maps of WSS and OSI, including statistical analysis provide a powerful tool to monitor local aortic hemodynamics during ageing and atherosclerosis. The correlation of spatially resolved hemodynamics and plaque characteristics could significantly improve our understanding of the impact of hemodynamics on atherosclerosis, which may be key to understand plaque progression towards vulnerability.
Atherosclerosis is an inflammatory disease of large and medium-sized arteries, characterized by the growth of atherosclerotic lesions (plaques). These plaques often develop at inner curvatures of arteries, branchpoints, and bifurcations, where the endothelial wall shear stress is low and oscillatory. In conjunction with other processes such as lipid deposition, biomechanical factors lead to local vascular inflammation and plaque growth. There is also evidence that low and oscillatory shear stress contribute to arterial remodeling, entailing a loss in arterial elasticity and, therefore, an increased pulse-wave velocity. Although altered shear stress profiles, elasticity and inflammation are closely intertwined and critical for plaque growth, preclinical and clinical investigations for atherosclerosis mostly focus on the investigation of one of these parameters only due to the experimental limitations. However, cardiovascular magnetic resonance imaging (MRI) has been demonstrated to be a potent tool which can be used to provide insights into a large range of biological parameters in one experimental session. It enables the evaluation of the dynamic process of atherosclerotic lesion formation without the need for harmful radiation. Flow-sensitive MRI provides the assessment of hemodynamic parameters such as wall shear stress and pulse wave velocity which may replace invasive and radiation-based techniques for imaging of the vascular
function and the characterization of early plaque development. In combination with inflammation imaging, the analyses and correlations of these parameters could not only significantly advance basic preclinical investigations of atherosclerotic lesion formation and progression, but also the diagnostic clinical evaluation for early identification of high-risk plaques, which are prone to rupture. In this review, we summarize the key applications of magnetic resonance imaging for the evaluation of plaque characteristics through flow sensitive and morphological measurements. The simultaneous measurements of functional and structural parameters will further preclinical research on atherosclerosis and has the potential to fundamentally improve the detection of inflammation and vulnerable plaques in patients.
Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study
(2022)
Objective
Immune checkpoint inhibitors can cause various immune-related adverse events including secondary hypophysitis. We compared clinical characteristics of immunotherapy-induced hypophysitis (IIH) and primary hypophysitis (PH)
Design
Retrospective multicenter cohort study including 56 patients with IIH and 60 patients with PH.
Methods
All patients underwent extensive endocrine testing. Data on age, gender, symptoms, endocrine dysfunction, MRI, immunotherapeutic agents and autoimmune diseases were collected.
Results
Median time of follow-up was 18 months in IIH and 69 months in PH. The median time from initiation of immunotherapy to IIH diagnosis was 3 months. IIH affected males more frequently than PH (p < 0.001) and led to more impaired pituitary axes in males (p < 0.001). The distribution of deficient adenohypophysial axes was comparable between both entities, however, central hypocortisolism was more frequent (p < 0.001) and diabetes insipidus considerably less frequent in IIH (p < 0.001). Symptoms were similar except that visual impairment occurred more rarely in IIH (p < 0.001). 20 % of IIH patients reported no symptoms at all. Regarding MRI, pituitary stalk thickening was less frequent in IIH (p = 0.009). Concomitant autoimmune diseases were more prevalent in PH patients before the diagnosis of hypophysitis (p = 0.003) and more frequent in IIH during follow-up (p = 0.002).
Conclusions
Clinically, IIH and PH present with similar symptoms. Diabetes insipidus very rarely occurs in IIH. Central hypocortisolism, in contrast, is a typical feature of IIH. Preexisting autoimmunity seems not to be indicative of developing IIH.
Mitotane is the only approved drug for advanced adrenocortical carcinoma (ACC) and no biomarkers are available to predict attainment of therapeutic plasma concentrations and clinical response. Aim of the study was to evaluate the suitability of cytochrome P450(CYP)2W1 and CYP2B6 single nucleotide polymorphisms (SNPs) as biomarkers. A multicenter cohort study including 182 ACC patients (F/M = 121/61) treated with mitotane monotherapy after radical resection (group A, n = 103) or in not completely resectable, recurrent or advanced disease (group B, n = 79) was performed. CYP2W1*2, CYP2W1*6, CYP2B6*6 and CYP2B6 rs4803419 were genotyped in germline DNA. Mitotane blood levels were measured regularly. Response to therapy was evaluated as time to progression (TTP) and disease control rate (DCR). Among investigated SNPs, CYP2W1*6 and CYP2B6*6 correlated with mitotane treatment only in group B. Patients with CYP2W1*6 (n = 21) achieved less frequently therapeutic mitotane levels (>14 mg/L) than those with wild type (WT) allele (76.2% vs 51.7%, p = 0.051) and experienced shorter TTP (HR = 2.10, p = 0.019) and lower DCR (chi-square = 6.948, p = 0.008). By contrast, 55% of patients with CYP2B6*6 vs. 28.2% WT (p = 0.016) achieved therapeutic range. Combined, a higher rate of patients with CYP2W1*6WT+CYP2B6*6 (60.6%) achieved mitotane therapeutic range (p = 0.034). In not completely resectable, recurrent or advanced ACC, CYP2W1*6 SNP was associated with a reduced probability to reach mitotane therapeutic range and lower response rates, whereas CYP2B6*6 correlated with higher mitotane levels. The association of these SNPs may predict individual response to mitotane.
Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family, which are involved in tumor development through the inhibition of caspases. Aim was to investigate the expression of livin and other members of its pathway in adrenocortical tumors and in the adrenocortical carcinoma (ACC) cell line NCI-H295R.
The mRNA expression of livin, its isoforms α and β, XIAP, CASP3 and DIABLO was evaluated by qRT-PCR in 82 fresh-frozen adrenal tissues (34 ACC, 25 adenomas = ACA, 23 normal adrenal glands = NAG). Livin protein expression was assessed by immunohistochemistry in 270 paraffin-embedded tissues (192 ACC, 58 ACA, 20 NAG). Livin, CASP3 and cleaved caspase-3 were evaluated in NCI-H295R after induction of livin overexpression.
Relative livin mRNA expression was significantly higher in ACC than in ACA and NAG (0.060 ± 0.116 vs 0.004 ± 0.014 and 0.002 ± 0.009, respectively, p < 0.01), being consistently higher in tumors than in adjacent NAG and isoform β more expressed than α. No significant differences in CASP3, XIAP and DIABLO levels were found among these groups. In immunohistochemistry, livin was localized in both cytoplasm and nuclei. The ratio between cytoplasmic and nuclear staining was significantly higher in ACC (1.51 ± 0.66) than in ACA (0.80 ± 0.35) and NAG (0.88 ± 0.27; p < 0.0001). No significant correlations were observed between livin expression and histopathological parameters or clinical outcome. In NCI-H295R cells, the livin overexpression slightly reduced the activation of CASP3, but did not correlate with cell viability.
In conclusion, livin is specifically over-expressed in ACC, suggesting that it might be involved in adrenocortical tumorigenesis and represent a new molecular marker of malignancy.
Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare subtype of lung cancer with poor clinical outcomes. Data on recurrence-free survival (RFS) in early and locally advanced pure LCNEC after complete resection (R0) are lacking. This study aims to evaluate clinical outcomes in this subgroup of patients and to identify potential prognostic markers. Methods: Retrospective multicenter study including patients with pure LCNEC stage I-III and R0 resection. Clinicopathological characteristics, RFS, and disease-specific survival (DSS) were evaluated. Univariate and multivariate analyses were performed. Results: 39 patients (M:F = 26:13), with a median age of 64 years (44–83), were included. Lobectomy (69.2%), bilobectomy (5.1%), pneumonectomy (18%), and wedge resection (7.7%) were performed mostly associated with lymphadenectomy. Adjuvant therapy included platinum-based chemotherapy and/or radiotherapy in 58.9% of cases. After a median follow-up of 44 (4–169) months, the median RFS was 39 months with 1-, 2- and 5-year RFS rates of 60.0%, 54.6%, and 44.9%, respectively. Median DSS was 72 months with a 1-, 2- and 5-year rate of 86.8, 75.9, and 57.4%, respectively. At multivariate analysis, age (cut-off 65 years old) and pN status were independent prognostic factors for both RFS (HR = 4.19, 95%CI = 1.46–12.07, p = 0.008 and HR = 13.56, 95%CI 2.45–74.89, p = 0.003, respectively) and DSS (HR = 9.30, 95%CI 2.23–38.83, p = 0.002 and HR = 11.88, 95%CI 2.28–61.84, p = 0.003, respectively). Conclusion: After R0 resection of LCNEC, half of the patients recurred mostly within the first two years of follow-up. Age and lymph node metastasis could help to stratify patients for adjuvant therapy.
Patients affected by gastroenteropancreatic–neuroendocrine tumors (GEP–NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), and vitamin D deficiency. In patients with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome associated with NET occurrence, bone damage may carry other consequences. Osteoporosis may negatively impact on the quality of life of these patients and can increment the cost of medical care since these patients usually live with their disease for a long time. However, recommendations suggesting screening to assess bone health in GEP–NET patients are missing. The aim of this review is to critically analyze evidence on the mechanisms that could have a potential impact on bone health in patients affected by GEP–NET, focusing on vitamin D and its role in GEP–NET, as well as on factors associated with MEN1 that could have an impact on bone homeostasis.
Background:
Competing risks methodology allows for an event-specific analysis of the single components of composite time-to-event endpoints. A key feature of competing risks is that there are as many hazards as there are competing risks. This is not always well accounted for in the applied literature.
Methods:
We advocate a simulation point of view for understanding competing risks. The hazards are envisaged as momentary event forces. They jointly determine the event time. Their relative magnitude determines the event type. 'Empirical simulations' using data from a recent study on cardiovascular events in diabetes patients illustrate subsequent interpretation. The method avoids concerns on identifiability and plausibility known from the latent failure time approach.
Results:
The 'empirical simulations' served as a proof of concept. Additionally manipulating baseline hazards and treatment effects illustrated both scenarios that require greater care for interpretation and how the simulation point of view aids the interpretation. The simulation algorithm applied to real data also provides for a general tool for study planning.
Conclusions:
There are as many hazards as there are competing risks. All of them should be analysed. This includes estimation of baseline hazards. Study planning must equally account for these aspects.
Prospective longitudinal follow‐up of left ventricular ejection fraction (LVEF) trajectories after acute cardiac decompensation of heart failure is lacking. We investigated changes in LVEF and covariates at 6‐months' follow‐up in patients with a predischarge LVEF ≤40%, and determined predictors and prognostic implications of LVEF changes through 18‐months' follow‐up.
Methods and Results
Interdisciplinary Network Heart Failure program participants (n=633) were categorized into subgroups based on LVEF at 6‐months' follow‐up: normalized LVEF (>50%; heart failure with normalized ejection fraction, n=147); midrange LVEF (41%–50%; heart failure with midrange ejection fraction, n=195), or persistently reduced LVEF (≤40%; heart failure with persistently reduced LVEF , n=291). All received guideline‐directed medical therapies. At 6‐months' follow‐up, compared with patients with heart failure with persistently reduced LVEF, heart failure with normalized LVEF or heart failure with midrange LVEF subgroups showed greater reductions in LV end‐diastolic/end‐systolic diameters (both P<0.001), and left atrial systolic diameter (P=0.002), more increased septal/posterior end‐diastolic wall‐thickness (both P<0.001), and significantly greater improvement in diastolic function, biomarkers, symptoms, and health status. Heart failure duration <1 year, female sex, higher predischarge blood pressure, and baseline LVEF were independent predictors of LVEF improvement. Mortality and event‐free survival rates were lower in patients with heart failure with normalized LVEF (P=0.002). Overall, LVEF increased further at 18‐months' follow‐up (P<0.001), while LV end‐diastolic diameter decreased (P=0.048). However, LVEF worsened (P=0.002) and LV end‐diastolic diameter increased (P=0.047) in patients with heart failure with normalized LVEF hospitalized between 6‐months' follow‐up and 18‐months' follow‐up.
Conclusions
Six‐month survivors of acute cardiac decompensation for systolic heart failure showed variable LVEF trajectories, with >50% showing improvements by ≥1 LVEF category. LVEF changes correlated with various parameters, suggesting multilevel reverse remodeling, were predictable from several baseline characteristics, and were associated with clinical outcomes at 18‐months' follow‐up. Repeat hospitalizations were associated with attenuation of reverse remodeling."
A liquid chromatography tandem mass spectrometry method for the analysis of ten kinase inhibitors (afatinib, axitinib, bosutinib,cabozantinib, dabrafenib, lenvatinib, nilotinib, osimertinib, ruxolitinib, and trametinib) in human serum and plasma for theapplication in daily clinical routine has been developed and validated according to the US Food and Drug Administration andEuropean Medicines Agency validation guidelines for bioanalytical methods. After protein precipitation of plasma samples withacetonitrile, chromatographic separation was performed at ambient temperature using a Waters XBridge® Phenyl 3.5μm(2.1×50 mm) column. The mobile phases consisted of water-methanol (9:1, v/v) with 10 mM ammonium bicarbonate as phase A andmethanol-water (9:1, v/v) with 10 mM ammonium bicarbonate as phase B. Gradient elution was applied at a flow rate of 400μL/min. Analytes were detected and quantified using multiple reaction monitoring in electrospray ionization positive mode. Stableisotopically labeled compounds of each kinase inhibitor were used as internal standards. The acquisition time was 7.0 min perrun. All analytes and internal standards eluted within 3.0 min. The calibration curves were linear over the range of 2–500 ng/mLfor afatinib, axitinib, bosutinib, lenvatinib, ruxolitinib, and trametinib, and 6–1500 ng/mL for cabozantinib, dabrafenib, nilotinib,and osimertinib (coefficients of correlation≥0.99). Validation assays for accuracy and precision, matrix effect, recovery,carryover, and stability were appropriate according to regulatory agencies. The rapid and sensitive assay ensures high throughputand was successfully applied to monitor concentrations of kinase inhibitors in patients.
Context
Primary aldosteronism (PA) is the most frequent form of endocrine hypertension. Besides its deleterious impact on cardiovascular target organ damage, PA is considered to cause osteoporosis.
Patients and methods
We assessed bone turnover in a subset of 36 postmenopausal women with PA. 18 patients had unilateral PA and were treated by adrenalectomy, whereas 18 patients had bilateral PA and received mineralocorticoid receptor antagonist (MRA) therapy respectively. 18 age- and BMI-matched females served as controls. To estimate bone remodeling, we measured the bone turnover markers intact procollagen 1 N-terminal propeptide, bone alkaline phosphatase, osteocalcin and tartrate resistant acid phosphatase 5b in plasma by chemiluminescent immunoassays at time of diagnosis and one year after initiation of treatment.
Study design
Observational longitudinal cohort study.
Setting
Tertiary care hospital.
Results
Compared with controls, patients with PA had mildly elevated osteocalcin at baseline (p = 0.013), while the other bone markers were comparable between both groups. There were no differences between the unilateral and the bilateral PA subgroup. One year after initiation of MRA treatment with spironolactone bone resorption and bone formation markers had significantly decreased in patients with bilateral PA. In contrast, patients adrenalectomized because of unilateral PA showed no significant change of bone turnover markers.
Conclusion
This study shows that aldosterone excess in postmenopausal women with PA is not associated with a relevant increase of bone turnover markers at baseline. However, we observed a significant decrease of bone markers in patients treated with spironolactone, but not in patients treated by adrenalectomy.
Background
Treatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising.
Materials and Methods
Primary ATC (n=93) and PDTC (n=47) tissue samples diagnosed 1997-2019 at five German tertiary care centers were assessed for PD-L1 expression by immunohistochemistry using Tumor Proportion Score (TPS). FGFR 1-4 mRNA was quantified in 31 ATC and 14 PDTC with RNAscope in-situ hybridization. Normal thyroid tissue (NT) and papillary thyroid carcinoma (PTC) served as controls. Disease specific survival (DSS) was the primary outcome variable.
Results
PD-L1 TPS≥50% was observed in 42% of ATC and 26% of PDTC specimens. Mean PD-L1 expression was significantly higher in ATC (TPS 30%) than in PDTC (5%; p<0.01) and NT (0%, p<0.001). 53% of PDTC samples had PD-L1 expression ≤5%. FGFR mRNA expression was generally low in all samples but combined FGFR1-4 expression was significantly higher in PDTC and ATC compared to NT (each p<0.001). No impact of PD-L1 and FGFR 1-4 expression was observed on DSS.
Conclusion
High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation.